Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):858–864. doi: 10.1128/aac.32.6.858

Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes.

F C Szoka Jr 1, C J Chu 1
PMCID: PMC172296  PMID: 2843083

Abstract

Phosphonoformate and phosphonoacetate encapsulated in liposomes have substantially greater activity against herpes simplex virus type 2 in Vero cell tissue culture than the nonencapsulated compounds at the same dose. Encapsulation of phosphonoformate in liposomes resulted in a 30-fold increase of the antiviral effect with no increase in cytotoxicity measured by inhibition of thymidine incorporation into normal Vero cells. Thus, the selectivity of the liposomal drug increased 27-fold compared with the nonencapsulated compound. Liposome encapsulation of phosphonoacetate at a ratio of 0.3 mumol/mumol of lipid resulted in a 150-fold increase of antiviral activity with a concomitant 250-fold increase in cytotoxicity. However, the selectivity of phosphonoacetate could be increased by reducing the drug-to-lipid ratio. Liposome uptake by Vero cells, measured by the cell association of a nonexchangeable radiolabeled lipid, plateaued after 24 h of incubation and saturated at 60 nmol of lipid per mg of cellular protein at a lipid concentration of 300 microM. The saturation of liposome uptake on the Vero cells may account for the 27-fold increase in selectivity observed with the liposomal phosphonoformate. The greater activity of the encapsulated phosphono compounds is most likely due to their increased transport into the cytoplasm; this occurs subsequent to the uptake and processing of the liposome in the lysosomes of the cell. Liposome encapsulation of these agents may result in superior efficacy against viral infections residing in endocytotically and phagocytically active cells such as macrophages.

Full text

PDF
858

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abra R. M., Schreier H., Szoka F. C. The use of a new radioactive-iodine labeled lipid marker to follow in vivo disposition of liposomes: comparison with an encapsulated aqueous space marker. Res Commun Chem Pathol Pharmacol. 1982 Aug;37(2):199–213. [PubMed] [Google Scholar]
  2. BARTLETT G. R. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed] [Google Scholar]
  3. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  4. Dijkstra J., van Galen W. J., Hulstaert C. E., Kalicharan D., Roerdink F. H., Scherphof G. L. Interaction of liposomes with Kupffer cells in vitro. Exp Cell Res. 1984 Jan;150(1):161–176. doi: 10.1016/0014-4827(84)90711-0. [DOI] [PubMed] [Google Scholar]
  5. Eppstein D. A., Barnett J. W., Marsh Y. V., Gosselin G., Imbach J. L. Xyloadenosine analogue of (A2'p)2A inhibits replication of herpes simplex viruses 1 and 2. Nature. 1983 Apr 21;302(5910):723–724. doi: 10.1038/302723a0. [DOI] [PubMed] [Google Scholar]
  6. Eriksson B., Larsson A., Helgstrand E., Johansson N. G., Oberg B. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta. 1980 Mar 28;607(1):53–64. doi: 10.1016/0005-2787(80)90220-8. [DOI] [PubMed] [Google Scholar]
  7. Farthing C. F., Dalgleish A. G., Clark A., McClure M., Chanas A., Gazzard B. G. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. AIDS. 1987 May;1(1):21–25. [PubMed] [Google Scholar]
  8. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986 Jul 11;233(4760):215–219. doi: 10.1126/science.3014648. [DOI] [PubMed] [Google Scholar]
  9. Gaub J., Pedersen C., Poulsen A. G., Mathiesen L. R., Ulrich K., Lindhardt B. O., Faber V., Gerstoft J., Hofmann B., Lernestedt J. O. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS. 1987 May;1(1):27–33. [PubMed] [Google Scholar]
  10. Heath T. D., Lopez N. G., Stern W. H., Papahadjopoulos D. 5-Fluoroorotate: a new liposome-dependent cytotoxic agent. FEBS Lett. 1985 Jul 22;187(1):73–75. doi: 10.1016/0014-5793(85)81217-5. [DOI] [PubMed] [Google Scholar]
  11. Heath T. D., Montgomery J. A., Piper J. R., Papahadjopoulos D. Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1377–1381. doi: 10.1073/pnas.80.5.1377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Helgstrand E., Eriksson B., Johansson N. G., Lannerö B., Larsson A., Misiorny A., Norén J. O., Sjöberg B., Stenberg K., Stening G. Trisodium phosphonoformate, a new antiviral compound. Science. 1978 Sep 1;201(4358):819–821. doi: 10.1126/science.210500. [DOI] [PubMed] [Google Scholar]
  13. Herrin T. R., Fairgrieve J. S., Bower R. R., Shipkowitz N. L. Synthesis and anti-herpes simplex activity of analogues of phosphonoacetic acid. J Med Chem. 1977 May;20(5):660–663. doi: 10.1021/jm00215a008. [DOI] [PubMed] [Google Scholar]
  14. Koff W. C., Fidler I. J. The potential use of liposome-mediated antiviral therapy. Antiviral Res. 1985 Jun;5(3):179–190. doi: 10.1016/0166-3542(85)90050-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Levy J. A., Shimabukuro J., McHugh T., Casavant C., Stites D., Oshiro L. AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology. 1985 Dec;147(2):441–448. doi: 10.1016/0042-6822(85)90146-1. [DOI] [PubMed] [Google Scholar]
  17. Lifson J. D., Reyes G. R., McGrath M. S., Stein B. S., Engleman E. G. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986 May 30;232(4754):1123–1127. doi: 10.1126/science.3010463. [DOI] [PubMed] [Google Scholar]
  18. Mao J. C., Otis E. R., von Esch A. M., Herrin T. R., Fairgrieve J. S., Shipkowitz N. L., Duff R. G. Structure-activity studies on phosphonoacetate. Antimicrob Agents Chemother. 1985 Feb;27(2):197–202. doi: 10.1128/aac.27.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mogensen S. C. Biological conditions influencing the focal necrotic hepatitis test for differentiation between herpes simplex virus types 1 and 2. Acta Pathol Microbiol Scand B. 1976 Jun;84(3):154–158. [PubMed] [Google Scholar]
  20. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1982;19(3):387–415. doi: 10.1016/0163-7258(82)90074-2. [DOI] [PubMed] [Google Scholar]
  21. Overby L. R., Duff R. G., Mao J. C. Antiviral potential of phosphonoacetic acid. Ann N Y Acad Sci. 1977 Mar 4;284:310–320. doi: 10.1111/j.1749-6632.1977.tb21966.x. [DOI] [PubMed] [Google Scholar]
  22. Overby L. R., Robishaw E. E., Schleicher J. B., Rueter A., Shipkowitz N. L., Mao J. C. Inhibition of herpes simplex virus replication by phosphonoacetic acid. Antimicrob Agents Chemother. 1974 Sep;6(3):360–365. doi: 10.1128/aac.6.3.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ringdén O., Lönnqvist B., Paulin T., Ahlmén J., Klintmalm G., Wahren B., Lernestedt J. O. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother. 1986 Mar;17(3):373–387. doi: 10.1093/jac/17.3.373. [DOI] [PubMed] [Google Scholar]
  24. Ruscetti F. W., Mikovits J. A., Kalyanaraman V. S., Overton R., Stevenson H., Stromberg K., Herberman R. B., Farrar W. L., Ortaldo J. R. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol. 1986 May 15;136(10):3619–3624. [PubMed] [Google Scholar]
  25. Sandstrom E. G., Kaplan J. C., Byington R. E., Hirsch M. S. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet. 1985 Jun 29;1(8444):1480–1482. doi: 10.1016/s0140-6736(85)92255-x. [DOI] [PubMed] [Google Scholar]
  26. Sodroski J., Goh W. C., Rosen C., Campbell K., Haseltine W. A. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. 1986 Jul 31-Aug 6Nature. 322(6078):470–474. doi: 10.1038/322470a0. [DOI] [PubMed] [Google Scholar]
  27. Sundquist B., Oberg B. Phosphonoformate inhibits reverse transcriptase. J Gen Virol. 1979 Nov;45(2):273–281. doi: 10.1099/0022-1317-45-2-273. [DOI] [PubMed] [Google Scholar]
  28. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Szoka F., Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9:467–508. doi: 10.1146/annurev.bb.09.060180.002343. [DOI] [PubMed] [Google Scholar]
  30. Szoka F., Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A. 1978 Sep;75(9):4194–4198. doi: 10.1073/pnas.75.9.4194. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES